Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25712795 | 1.00 | CES2 (0.31) | CES2ALDH1A1TP53TSHRHIF1A | |
| SCHEMBL2639316 | 1.00 | CES2 (0.31) | CES2ALDH1A1TP53TSHRHIF1A | |
| SCHEMBL5786379 | 1.00 | CES2 (0.31) | CES2ALDH1A1TP53TSHRHIF1A | |
| SCHEMBL3378003 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL18245677 | 0.92 | LMNA (0.32) | CES2ALDH1A1TP53HSD17B10 | |
| SCHEMBL22296985 | 0.91 | CES2 (0.42) | CES2TSHR | |
| SCHEMBL6668639 | 0.89 | CES2 (0.36) | CES2ALDH1A1TP53TSHRHIF1A | |
| SCHEMBL22325195 | 0.89 | CES2 (0.36) | CES2ALDH1A1TP53TSHRHIF1A | |
| SCHEMBL30661132 | 0.89 | CES2 (0.36) | CES2ALDH1A1TP53TSHRHIF1A | |
| SCHEMBL6712841 | 0.89 | CES2 (0.36) | CES2ALDH1A1TP53TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128794-A1 | FATTY ACID CONJUGATED CYCLIC PEPTIDES | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| US-20220127226-A1 | ANTI-ARRHYTHMICITY AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-28 | — | — | US | claimed |
| US-20200190157-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | SAINT LOUIS UNIVERSITY (US) | 2020-06-18 | — | — | US | claimed |
| WO-2019023295-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | SAINT LOUIS UNIVERSITY (US) | 2019-01-31 | — | — | WO | claimed |
| US-20170362173-A1 | ANTI-ARRHYTHMICITY AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-21 | — | — | US | claimed |
| US-20170226080-A1 | PYRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2017-08-10 | — | — | US | claimed |
| EP-3177603-A1 | PYRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS | Merck Patent GmbH (DE) | 2017-06-14 | — | — | EP | claimed |
| WO-2016020031-A1 | PYRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-02-11 | — | — | WO | claimed |
| EP-1578424-A4 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A| QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2007-08-08 | — | — | EP | claimed |
| US-7135480-B2 | Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers | CYTOVIA, INC. (US) | 2006-11-14 | — | — | US | claimed |
| EP-1578424-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2005-01-20 | — | — | US | claimed |
| WO-2004055163-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A]QUINOLINES | CYTOVIA, INC. (US) | 2004-07-01 | — | — | WO | claimed |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| WO-2025128794-A1 | FATTY ACID CONJUGATED CYCLIC PEPTIDES | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2025-06-17 | — | — | US | disclosed |
| US-20060138083-A1 | Patterning and alteration of molecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-29 | — | — | US | disclosed |
| EP-1578424-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004055163-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A]QUINOLINES | CYTOVIA, INC. (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226080-A1 | PYRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS | METAP1, METAP2, DNPEP | CES2 1977/4885ALDH1A1 1138/4885TP53 766/4885 |
| US-20170362173-A1 | ANTI-ARRHYTHMICITY AGENTS | KCNH1, TNNI3, TNNC1 | CES2 467/4885ALDH1A1 806/4885TP53 4850/4885 |
| US-20200190157-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | FABP2, FGFR2, FGF2 | CES2 3360/4885ALDH1A1 3662/4885TP53 4821/4885 |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | CES2 2886/4885ALDH1A1 4851/4885TP53 1632/4885 |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | CES2 1945/4885ALDH1A1 4242/4885TP53 980/4885 |
| US-20220127226-A1 | ANTI-ARRHYTHMICITY AGENTS | KCNH1, TNNI3, TNNC1 | CES2 467/4885ALDH1A1 806/4885TP53 4850/4885 |
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CASP3, CASP7, CASP1 | CES2 1524/4885ALDH1A1 1061/4885TP53 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.